GeneDx Holdings Management
Management criteria checks 3/4
GeneDx Holdings' CEO is Katherine Stueland, appointed in May 2022, has a tenure of 2.58 years. total yearly compensation is $3.58M, comprised of 18.9% salary and 81.1% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $5.55M. The average tenure of the management team and the board of directors is 1.2 years and 3.4 years respectively.
Key information
Katherine Stueland
Chief executive officer
US$3.6m
Total compensation
| CEO salary percentage | 18.9% |
| CEO tenure | 2.6yrs |
| CEO ownership | 0.3% |
| Management average tenure | 1.2yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Is GeneDx Holdings (NASDAQ:WGS) Using Too Much Debt?
Dec 16
GeneDx: Possibly Turning A Profit In 2025 (Rating Downgrade)
Dec 16GeneDx Rides Revenue Surge, But Valuation Risks Loom
Dec 09GeneDx Holdings Corp.'s (NASDAQ:WGS) P/S Is Still On The Mark Following 40% Share Price Bounce
Nov 23US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results
Nov 01GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
Oct 30GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
Oct 21After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar
Oct 04Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?
Aug 29GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform
Aug 19Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher
Jul 27GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors
Jun 12GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
Jun 06Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce
Apr 24GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13
Feb 23The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More
Feb 22Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified
Dec 20Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)
Nov 02Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%
Nov 01Sema4 names Kevin Feeley as CFO
Aug 26Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade
Aug 20Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 19Sema4 Q2 2022 Earnings Preview
Aug 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$83m |
| Jun 30 2024 | n/a | n/a | -US$117m |
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$4m | US$675k | -US$176m |
| Sep 30 2023 | n/a | n/a | -US$459m |
| Jun 30 2023 | n/a | n/a | -US$494m |
| Mar 31 2023 | n/a | n/a | -US$533m |
| Dec 31 2022 | US$12m | US$454k | -US$549m |
Compensation vs Market: Katherine's total compensation ($USD3.58M) is below average for companies of similar size in the US market ($USD5.50M).
Compensation vs Earnings: Katherine's compensation has been consistent with company performance over the past year.
CEO
Katherine Stueland (48 yo)
2.6yrs
Tenure
US$3,575,335
Compensation
Ms. Katherine A. Stueland serves as Chief Executive Officer & Director at GeneDx Holdings Corp. (formerly known as Sema4 Holdings Corp.) since May 2022 and serves as its President. She served as President...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.6yrs | US$3.58m | 0.26% $ 5.6m | |
| Chief Financial Officer | 2.3yrs | US$1.57m | 0.10% $ 2.2m | |
| Head of Operations | 1.2yrs | no data | no data | |
| Chief Product & Technology Officer | less than a year | no data | no data | |
| Chief Legal Officer | less than a year | no data | no data | |
| Head of People Strategy | less than a year | no data | no data | |
| Chief Medical Officer | 2.6yrs | no data | no data | |
| Chief Growth Officer | 1.3yrs | no data | no data | |
| Chief of Staff | no data | no data | no data | |
| Head of Medical Affairs | less than a year | no data | no data |
1.2yrs
Average Tenure
48yo
Average Age
Experienced Management: WGS's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.6yrs | US$3.58m | 0.26% $ 5.6m | |
| Independent Director | 7.1yrs | US$162.00k | 0.71% $ 15.2m | |
| Director | 2.7yrs | US$147.00k | 0.10% $ 2.2m | |
| Independent Director | 2.9yrs | US$162.00k | 0.026% $ 562.4k | |
| Independent Director | 4.4yrs | US$154.50k | 0.028% $ 592.6k | |
| Chairman of the Board | 3.4yrs | US$992.46k | 0.53% $ 11.4m | |
| Independent Director | 4.3yrs | US$160.75k | 0.030% $ 651.8k |
3.4yrs
Average Tenure
50.5yo
Average Age
Experienced Board: WGS's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 02:38 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GeneDx Holdings Corp. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |
| Matthew Sykes | Goldman Sachs |